1-8 of 8
Michelle D. Garrett
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

The Association of PI3 Kinase Signaling and Chemoresistance in Advanced Ovarian Cancer

Craig P. Carden, Adam Stewart, Parames Thavasu, Emma Kipps, Lorna Pope, Mateus Crespo, Susana Miranda, Gerhardt Attard, Michelle D. Garrett, Paul A. Clarke, Paul Workman, Johann S. de Bono, Martin Gore, Stan B Kaye, Udai Banerji
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2012) 11 (7): 1609–1617.
https://doi.org/10.1158/1535-7163.MCT-11-0996
Published: 05 July 2012
View article titled, The Association of PI3 Kinase Signaling and Chemoresistance in Advanced Ovarian Cancer
Open the PDF for The Association of PI3 Kinase Signaling and Chemoresistance in Advanced Ovarian Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract B190: Pharmacokinetics of the AKT inhibitor CCT128930 from dried blood spots sampled from caudal bleeding compared with conventional cardiac puncture.

Florence I. Raynaud, Angela Hayes, Yasmin J. Asad, Louise Johnson, Alan T. Henley, John J. Caldwell, Ian Collins, Michelle D. Garrett
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): B190.
https://doi.org/10.1158/1535-7163.TARG-11-B190
Published: 12 November 2011
View article titled, Abstract B190: Pharmacokinetics of the AKT inhibitor CCT128930 from dried blood spots sampled from caudal bleeding compared with conventional cardiac puncture.
Journal Articles

Abstract A228: CCT244747 is a novel, potent and selective inhibitor of CHK1 with oral efficacy both alone in neuroblastoma and in combination with genotoxic chemotherapeutic agents.

Michael I. Walton, Paul E. Eve, Angela Hayes, Melanie R. Valenti, Alexis K. de Haven Brandon, Gary Box, Albert Hallsworth, Elizabeth L. Smith, Kathy J. Boxall, Michael Lainchbury, Thomas P. Matthews, Yann Jamin, Simon P. Robinson, G. Wynne Aherne, John C. Reader, Louis Chesler, Florence I. Raynaud, Suzanne E. Eccles, Ian Collins, Michelle D. Garrett
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): A228.
https://doi.org/10.1158/1535-7163.TARG-11-A228
Published: 12 November 2011
View article titled, Abstract A228: CCT244747 is a novel, potent and selective inhibitor of CHK1 with oral efficacy both alone in neuroblastoma and in combination with genotoxic chemotherapeutic agents.
Journal Articles

Abstract A235: Structure-guided evolution of potent and selective oral inhibitors of CHK1 through scaffold morphing.

Thomas P. Matthews, Suki Klair, Kwai-Ming J. Cheung, Jane Scanlon, Michael Lainchbury, Nelly Piton, Martin Fisher, Michael Cherry, Kathy Boxall, Michael I. Walton, Isaac M. Westwood, Angela Hayes, Paul Eve, Melanie Valenti, Alexis de Haven Brandon, Gary Box, Rob L. M. van Montfort, David H. Williams, Wynne Aherne, Florence I. Raynaud, Suzanne A. Eccles, Michelle D. Garrett, John C. Reader, Ian Collins
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): A235.
https://doi.org/10.1158/1535-7163.TARG-11-A235
Published: 12 November 2011
View article titled, Abstract A235: Structure-guided evolution of potent and selective oral inhibitors of CHK1 through scaffold morphing.
Journal Articles

Preclinical Pharmacology, Antitumor Activity, and Development of Pharmacodynamic Markers for the Novel, Potent AKT Inhibitor CCT128930

Timothy A. Yap, Mike I. Walton, Lisa-Jane K. Hunter, Melanie Valenti, Alexis de Haven Brandon, Paul D. Eve, Ruth Ruddle, Simon P. Heaton, Alan Henley, Lisa Pickard, Gowri Vijayaraghavan, John J. Caldwell, Neil T. Thompson, Wynne Aherne, Florence I. Raynaud, Suzanne A. Eccles, Paul Workman, Ian Collins, Michelle D. Garrett
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (2): 360–371.
https://doi.org/10.1158/1535-7163.MCT-10-0760
Published: 08 February 2011
View article titled, Preclinical Pharmacology, Antitumor Activity, and Development of Pharmacodynamic Markers for the Novel, Potent AKT Inhibitor CCT128930
Open the PDF for Preclinical Pharmacology, Antitumor Activity, and Development of Pharmacodynamic Markers for the Novel, Potent AKT Inhibitor CCT128930 in another window
Includes: Supplementary data
Journal Articles

AT7867 Is a Potent and Oral Inhibitor of AKT and p70 S6 Kinase That Induces Pharmacodynamic Changes and Inhibits Human Tumor Xenograft Growth

Kyla M. Grimshaw, Lisa-Jane K. Hunter, Timothy A. Yap, Simon P. Heaton, Mike I. Walton, Steven J. Woodhead, Lynsey Fazal, Matthias Reule, Thomas G. Davies, Lisa C. Seavers, Victoria Lock, John F. Lyons, Neil T. Thompson, Paul Workman, Michelle D. Garrett
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2010) 9 (5): 1100–1110.
https://doi.org/10.1158/1535-7163.MCT-09-0986
Published: 09 May 2010
View article titled, AT7867 Is a Potent and Oral Inhibitor of AKT and p70 S6 Kinase That Induces Pharmacodynamic Changes and Inhibits Human Tumor Xenograft Growth
Open the PDF for AT7867 Is a Potent and Oral Inhibitor of AKT and p70 S6 Kinase That Induces Pharmacodynamic Changes and Inhibits Human Tumor Xenograft Growth in another window
Journal Articles

The Preclinical Pharmacology and Therapeutic Activity of the Novel CHK1 Inhibitor SAR-020106

Michael I. Walton, Paul D. Eve, Angela Hayes, Melanie Valenti, Alexis De Haven Brandon, Gary Box, Kathy J. Boxall, G. Wynne Aherne, Suzanne A. Eccles, Florence I. Raynaud, David H. Williams, John C. Reader, Ian Collins, Michelle D. Garrett
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2010) 9 (1): 89–100.
https://doi.org/10.1158/1535-7163.MCT-09-0938
Published: 12 January 2010
View article titled, The Preclinical Pharmacology and Therapeutic Activity of the Novel CHK1 Inhibitor SAR-020106
Open the PDF for The Preclinical Pharmacology and Therapeutic Activity of the Novel CHK1 Inhibitor SAR-020106 in another window
Includes: Supplementary data
Journal Articles

Abstract B135: First‐in‐man, first‐in‐class phase I study of two schedules of MK‐2206, a novel oral Akt inhibitor, in patients (pts) with advanced solid tumors, including ovarian and castration resistant prostate cancer (CRPC)

Timothy A. Yap, Kyriakos Papadopoulos, Ivy Fearen, Christopher Carpenter, Liliana Delgado, Adekemi Taylor, Julia Domsch, David Olmos, Andre T. Brunetto, Daniel S. Tan, Shaun Decordova, Simon P. Heaton, Michelle D. Garrett, Amita Patnaik, Daniel Sullivan, Li Yan, Johann S. de Bono, Anthony W. Tolcher
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (12_Supplement): B135.
https://doi.org/10.1158/1535-7163.TARG-09-B135
Published: 10 December 2009
View article titled, Abstract B135: First‐in‐man, first‐in‐class phase I study of two schedules of MK‐2206, a novel oral Akt inhibitor, in patients (pts) with advanced solid tumors, including ovarian and castration resistant prostate cancer (CRPC)